SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096220
Filing Date
2024-08-13
Accepted
2024-08-13 16:13:15
Documents
57
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q awh-20240630.htm   iXBRL 10-Q 1771374
2 EX-10.3 awh-ex10_3.htm EX-10.3 29531
3 EX-10.4 awh-ex10_4.htm EX-10.4 23714
4 EX-10.5 awh-ex10_5.htm EX-10.5 128660
5 EX-31.1 awh-ex31_1.htm EX-31.1 14253
6 EX-31.2 awh-ex31_2.htm EX-31.2 14362
7 EX-32.1 awh-ex32_1.htm EX-32.1 10345
  Complete submission text file 0000950170-24-096220.txt   7642962

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT awh-20240630.xsd EX-101.SCH 1129232
60 EXTRACTED XBRL INSTANCE DOCUMENT awh-20240630_htm.xml XML 1180482
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 241201603
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)